WPA
NVO

West Paces Advisors’s Novo Nordisk NVO Stock Holding History

West Paces Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40
Closed -$4.76K – 570
2024
Q3 		$4.76K Sell
40
-300
-88% -$40K ﹤0.01% 387
2024
Q2 		$48.5K Sell
340
-40
-11% -$5.3K 0.01% 220
2024
Q1 		$48.8K Hold
380
– – 0.01% 233
2023
Q4 		$39.3K Buy
380
+80
+27% +$7.91K 0.01% 246
2023
Q3 		$27.3K Hold
300
– – 0.01% 270
2023
Q2 		$24.3K Hold
300
– – 0.01% 288
2023
Q1 		$23.9K Hold
300
– – 0.01% 288
2022
Q4 		$20.3K Hold
300
– – 0.01% 290
2022
Q3 		$14.9K Buy
+300
New +$16.1K 0.01% 304
2017
Q1 		– Sell
-500
Closed -$8.71K – 530
2016
Q4 		$8.96K Buy
+500
New +$9.06K 0.01% 348

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

West Paces Advisors's NVO Position: Q4 2024 in Review

West Paces Advisors sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 40 shares — an estimated $4.76K sold.

West Paces Advisors first reported a position in NVO in Q4 2016 and held it in 10 quarters. The position peaked at $48.8K in Q1 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • West Paces Advisors reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • West Paces Advisors sold 40 Novo Nordisk shares in Q4 2024, an estimated $4.76K.
  • West Paces Advisors first reported a position in Novo Nordisk in Q4 2016 and held it in 10 quarters.
  • West Paces Advisors's Novo Nordisk position peaked at $48.8K in Q1 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on West Paces Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.